Clinical Trial

Clinical and Radiographic Evaluation of Vital Pulpotomy Techniques in Primary Molars Using of Premixed Bioactive Bioceramic MTA (Neo-putty) as a Novel Pulpotomy Medication Versus Formocresol

Recruiting
View on ClinicalTrials.gov →
Summary
Despite the benefit of formocresol, there are toxic effects allergic reactions and local soft and hard tissue necrosis have been reported when such formaldehyde compounds were used clinically, however, the adverse effect of the clinically used of this compound are not widely reported. It has been stated that it has a side effect on the permanent successor although it results as a successful technique for the treatment of the primary teeth
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-02-23; most recent amendment 2024-12-18.
Status change: Not Yet Recruiting → Recruiting 2024-12-18
Trial Details
NCT Number NCT06288477
Lead Sponsor October University for Modern Sciences and Arts
Conditions Vital, Pulpotomy, Techniques
Enrollment 44 participants
Start Date 2024-03-20
Primary Completion 2024-05-01 (estimated)
Study Completion 2025-02-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-20